ZG005 with bevacizumab vs sintilimab with bevacizumab for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer that has spread or cannot be surgically removed.
- You can still perform daily activities with little or no help (ECOG 0 or 1).
- Your doctor expects you to live at least 12 more weeks.
- You are able to understand and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a new drug called ZG005 combined with standard chemotherapy for people with advanced gallbladder cancer. The goal is to see if adding ZG005 helps shrink tumors or slow the disease.
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.